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Summary
Background Human metapneumovirus is a common virus associated with acute lower respiratory infections (ALRIs) 
in children. No global burden estimates are available for ALRIs associated with human metapneumovirus in children, 
and no licensed vaccines or drugs exist for human metapneumovirus infections. We aimed to estimate the age-
stratified human metapneumovirus-associated ALRI global incidence, hospital admissions, and mortality burden in 
children younger than 5 years.
Methods We estimated the global burden of human metapneumovirus-associated ALRIs in children younger than 
5 years from a systematic review of 119 studies published between Jan 1, 2001, and Dec 31, 2019, and a further 40 high 
quality unpublished studies. We assessed risk of bias using a modified Newcastle-Ottawa Scale. We estimated 
incidence, hospital admission rates, and in-hospital case-fatality ratios (hCFRs) of human metapneumovirus-
associated ALRI using a generalised linear mixed model. We applied incidence and hospital admission rates of 
human metapneumovirus–associated ALRI to population estimates to yield the morbidity burden estimates by age 
bands and World Bank income levels. We also estimated human metapneumovirus-associated ALRI in-hospital 
deaths and overall human metapneumovirus-associated ALRI deaths (both in-hospital and non-hospital deaths). 
Additionally, we estimated human metapneumovirus-attributable ALRI cases, hospital admissions, and deaths by 
combining human metapneumovirus-associated burden estimates and attributable fractions of human 
metapneumovirus in laboratory-confirmed human metapneumovirus cases and deaths.
Findings In 2018, among children younger than 5 years globally, there were an estimated 14·2 million human 
metapneumovirus-associated ALRI cases (uncertainty range [UR] 10·2 million to 20·1 million), 643 000 human 
metapneumovirus-associated hospital admissions (UR 425 000 to 977 000), 7700 human metapneumovirus-associated 
in-hospital deaths (2600 to 48 800), and 16 100 overall (hospital and community) human metapneumovirus-associated 
ALRI deaths (5700 to 88 000). An estimated 11·1 million ALRI cases (UR 8·0 million to 15·7 million), 502 000 ALRI 
hospital admissions (UR 332 000 to 762 000), and 11 300 ALRI deaths (4000 to 61 600) could be causally attributed to 
human metapneumovirus in 2018. Around 58% of the hospital admissions were in infants under 12 months, and 
64% of in-hospital deaths occurred in infants younger than 6 months, of which 79% occurred in low-income and 
lower-middle-income countries.
Interpretation Infants younger than 1 year have disproportionately high risks of severe human metapneumovirus 
infections across all World Bank income regions and all child mortality settings, similar to respiratory syncytial virus 
and influenza virus. Infants younger than 6 months in low-income and lower-middle-income countries are at greater 
risk of death from human metapneumovirus-associated ALRI than older children and those in upper-middle-income 
and high-income countries. Our mortality estimates demonstrate the importance of intervention strategies for infants 
across all settings, and warrant continued efforts to improve the outcome of human metapneumovirus-associated 
ALRI among young infants in low-income and lower-middle-income countries.
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Acute lower respiratory infections (ALRIs) are one of the 
leading causes of morbidity and mortality in children 
globally, accounting for 10% of deaths in children younger 
than 5 years in 2017.1 Human metapneumovirus, first 
identified in 2001, is an important virus that causes ALRIs 
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in young children.2–5 Previous evidence indicates that most 
children are infected with human metapneumovirus 
by age 5 years, with most severe infections occurring 
in infants, including symptomatic and asymptomatic 
infections.6–10 Pooled analyses have shown that human 
metapneumovirus is associated with 6·1–6·4% of hospital 
admissions due to ALRI among patients younger than 
20 years worldwide.11,12 Few studies have reported the 
incidence and mortality for human metapneumovirus-
associated ALRIs, and studies have rarely reported disease 
burden in narrower age groups (eg, those younger than 
6 months). No global or regional burden estimates are 
available for children under 5 years.
A live-attenuated recombinant human metapneumo-
virus vaccine has been assessed in a phase 1 clinical 
trial; however, study findings showed that the vaccine 
had insufficient immunogenicity in children aged 
6–59 months.13 Antivirals against human meta pneumo-
virus infections and several other types of vaccines have 
been investigated, but have not reached clinical trials.14–16
We aimed to estimate the global and regional number 
of human metapneumovirus-associated ALRI cases, 
hospital admissions, and mortality by age strata in 
children under 5 years for 2018, using published and 
unpublished data on laboratory-confirmed (culture, 
immunofluorescence assay, or molecular test) human 
metapneumovirus morbidity and mortality. Since the 
presence of human metapneumovirus in the upper 
respiratory tract in children does not indicate that 
ALRI symptoms were directly caused by these viruses, 
we also estimated the global burden of ALRI that is 
attributable to human metapneumovirus by accounting 
Research in context
Evidence before this study
Human metapneumovirus is a common virus in children with 
acute lower respiratory infection (ALRI). Two pooled analyses 
have shown that human metapneumoviruses are identified in 
6·1–6·4% of ALRIs in patients younger than 20 years globally. 
However, no global estimates of human metapneumovirus-
associated ALRI burden are available for children younger than 
5 years. The estimation of global human metapneumovirus 
burden is challenging due to the paucity of population-based 
studies on the incidence of human metapneumovirus infections.
Added value of this study
We did a meta-analysis based on published and unpublished 
data on laboratory-confirmed human metapneumovirus-
associated ALRI incidence, hospital admissions, and mortality 
burden. We included 159 studies with data on human 
metapneumovirus-associated ALRI community incidence, 
hospital admission rates, proportion of human 
metapneumovirus-positive cases among hospitalised ALRI 
cases, and in-hospital case-fatality ratios, which included 
40 high quality unpublished studies that provided data stratified 
by narrow age groups in children younger than 5 years. 27% of 
the studies were from low-income and lower-middle-income 
countries. Our estimates of human metapneumovirus-
associated ALRI burden were stratified by the level of child 
mortality of the setting and by age groups, from which we 
identified the population subgroups most susceptible to human 
metapneumovirus-associated ALRI morbidity and mortality, 
identifying target populations and settings for future 
intervention studies and informing intervention strategies. 
Since the presence of human metapneumovirus in the upper 
respiratory tract in children with ALRIs does not indicate 
causation, we reported the global burden of ALRIs that are 
causally attributable to human metapneumovirus (human 
metapneumovirus-attributable ALRI burden), which could aid 
understanding with regard to the involvement of this virus in 
causing childhood ALRI. We estimated that human 
metapneumovirus could be identified in 11% of ALRI cases, 
4–13% of hospital admissions due to ALRIs, and 2% of ALRI 
deaths among children under 5 years globally, using our 
estimates in conjunction with previously published all-cause 
ALRI burden estimates. After accounting for the causal 
attribution of human metapneumovirus, we estimated that 
8% of ALRI cases, 3–10% of hospital admissions due to ALRIs, 
and 1% of ALRI-associated mortality could be attributed to 
human metapneumovirus. About 58% of these hospital 
admissions occurred in the first year of life. About 64% of the 
in-hospital deaths occurred in infants younger than 6 months, 
including 79% occurring in low-income and lower-middle-
income countries.
Implications of all the available evidence
To our knowledge, our systematic review provides the first 
estimates of global human metapneumovirus-associated 
ALRIs and human metapneumovirus-attributable ALRI 
morbidity and mortality in children under 5 years overall and 
stratified by narrow age bands (0–5 months, 6–11 months, 
and 12–59 months). Our results indicate that infants younger 
than 1 year have an increased risk of severe human 
metapneumovirus-associated ALRIs compared with older 
children. Infants younger than 6 months, especially those in 
low-income and lower-middle-income countries, are at 
greater risk of death from human metapneumovirus-
associated ALRIs than older infants and those from upper 
middle-income countries and high-income countries. These 
findings warrant continued efforts to develop targeted 
intervention strategies to protect infants from human 
metapneumovirus infections, and to improve the outcome of 
infants with human metapneumovirus-associated ALRIs, 
especially in low-income and lower-middle income countries. 
Such strategies could include specific antiviral therapeutics, 
monoclonal antibodies, or vaccination for children and their 
mothers during pregnancy.
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for the causal attribution of human metapneumovirus. 
The estimates would provide evidence for the further 
development of targeted interventions and treatment.
Methods
Systematic review
We did a systematic review of the human meta-
pneumovirus-associated ALRI disease burden in children 
under 5 years (appendix pp 4–5). We searched MEDLINE 
(Ovid), Embase (Ovid), Global Health 1973 onwards 
(Ovid), CINAHL, Web of Science, Global Health Library, 
and three Chinese databases (CNKI, Wanfang, and 
Chongqing VIP) for studies published between Jan 1, 2001, 
and Dec 31, 2019. To search the grey literature, we did 
broad searches through Google using the same date 
restrictions and the search terms “acute respiratory 
infections” AND “child” AND “parainfluenza virus”. No 
language or publication restrictions were applied. Three 
authors (XW, LCV, and YL) screened the titles and 
abstracts for eligibility and extracted data independently. 
Disagreements were resolved by discussion between the 
authors.
We included studies that reported any of the following 
data in children younger than 5 years: community inci-
dence rates of ALRIs (ie, clinical pneumonia according 
to 2005 WHO Integrated Management of Childhood 
Illnesses17) with laboratory-confirmed human meta-
pneumo virus; rates of hospital admissions for ALRIs 
(ie, physician-confirmed diagnosis of ALRI) or ALRIs 
with hypoxaemia confirmed by pulse oximetry both 
with laboratory-confirmed human metapneumo virus 
(per 1000 children per year); proportion of ALRIs with 
laboratory-confirmed human metapneumovirus cases 
among hospitalised ALRI cases; or in-hospital case-
fatality ratios (hCFRs) of ALRIs with laboratory-
confirmed human metapneumovirus. Case definitions 
are included in the appendix (pp 2–3).18
Studies had to use clear case definitions for specimen 
collection and testing, and studies that reported incidence 
and hospital admission rate data had to include data for 
at least one complete calendar year (or at least one full 
season if in a temperate region). We included hCFR 
data for any length of study period. We included data on 
the proportion of human metapneumovirus-positive 
cases among hospitalised ALRI cases if reported for at 
least one full calendar year.
We excluded studies: without a clear denominator 
population at risk (limited to those reporting incidence 
and hospital admission rate data); those in which human 
metapneumovirus was not the primary outcome; those 
reporting modelled burden estimates; those in which 
human metapneumovirus infections were diagnosed on 
the basis of serology alone; and those only including 
population subgroups with high-risk conditions.
We supplemented data from published studies with 
high quality unpublished data (from ongoing studies or 
re-analysis of previously published studies) using agreed 
standardised approaches and definitions within the 
collaborative Respiratory Virus Global Epidemiology 
Network.19
Assessment of risk of biases
We used a modified Newcastle-Ottawa Scale to assess the 
risk of bias in seven domains, including study design, 
adjustment for health utilisation, patient groups excluded, 
definition, sampling strategy, diagnostic testing, and 
hypoxaemia ascertainment (appendix pp 25–26).18,20
Statistical analysis
Our burden estimation approaches, including main 
analyses and sensitivity analyses, are summarised in the 
appendix (p 14). We estimated the number of human 
metapneumovirus-associated ALRI cases, hospital admis-
sions, and in-hospital deaths using a similar strategy to 
our previous analysis.18 For the incidence rate and hospital 
admission rate, we scaled the population-at-risk for the 
level of testing per study where available before meta-
analyses (appendix p 23). In a meta-analysis, we estimated 
incidence rates, hospital admission rates, and hCFRs of 
human metapneumovirus-associated ALRI using a 
generalised linear mixed model.21
After meta-analyses, we estimated number of cases 
and number of hospital admissions using Monte Carlo 
simulation, which enabled the combination of meta-
estimates and population estimates (UN 2018 population 
estimates).22 The median value of 10 000 samples 
simulated from a log-normal distribution was used 
as the point burden estimate and the 2∙5th and 
97∙5th percentiles as the 95% uncertainty ranges (URs). 
We used the same strategy as our previous studies, for 
consistency; alternative methods (such as resampling 
observed data) are likely to yield comparable estimates.23 
In the main analysis, we reported estimates stratified 
by three non-overlapping age groups (0–5 months, 
6–11 months, and 12–59 months) and by child mortality 
level of the setting from 2018 data (stratified into low or 
high; using the median under-5 mortality rate [16·6 per 
1000 livebirths] as the cutoff point) for each outcome 
where available.24 Global results were calculated as the 
sum of age-specific and region-specific estimates. The 
numbers of cases were rounded to the nearest thousand, 
and deaths were rounded to the nearest hundred. In 
the community setting, we reported the incidence rate 
for the overall age group (0–59 months) because data 
were insufficient to allow disaggregation by narrower 
age bands. To incorporate information from studies 
with data for other age bands (eg, 0–11 months), we 
imputed the numbers of cases for 0–59 months using a 
multiple imputation approach as previously described 
(appendix pp 21–22).18
We estimated human metapneumovirus-associated 
ALRI in-hospital deaths by combining the estimates 
of hospital admissions and hCFRs of human meta-
pneumo virus-associated ALRIs.18,19 Similar to morbidity 
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estimation, global estimates of mortality were calculated 
as the sum of the estimates, stratified by the three age 
groups and by child mortality settings.
Many child deaths from ALRIs occur outside of 
hospitals, especially in resource-limited settings due to 
low care-seeking or restricted access to care. Thus, we 
estimated an inflation factor ratio of overall ALRI deaths 
to in-hospital ALRI deaths at eight sites in six countries 
with high child mortality (Mozambique, Kenya, South 
Africa, Burkina Faso, and Ghana in sub-Saharan Africa, 
and Bangladesh in south Asia).18,25–27 We calculated the 
median inflation factor, which was extrapolated to other 
countries with high child mortality, and we applied this 
inflation factor to estimates of in-hospital deaths to 
yield overall human metapneumovirus-associated ALRI 
mortality (appendix p15).18,19,28 We assumed that human 
metapneumovirus prevalence was the same in ALRI 
community deaths and in-hospital deaths. For settings 
with low child mortality, the reciprocal of the proportion 
of children with pneumonia symptoms who received 
care, measured in Multiple Indicator Cluster Surveys, 
Demographic and Health Surveys, and other national 
surveys, was used as a proxy for the inflation factor.29 
The inflation factor can be calculated for many countries 
and regions, and it can thus help improve the estimates 
of overall human metapneumovirus-associated ALRI 
mortality. The median inflation factor for low child 
mortality settings was extrapolated to other countries 
with low child mortality without available data. Compared 
with approximating the inflation factor using non-
specific ALRI mortality, in this approach we additionally 
assumed that the case-fatality ratios for pneumonia in 
hospitalised and non-hospitalised cases were broadly 
similar.
The presence of human metapneumovirus in the 
upper respiratory tract of a child with ALRI does not 
indicate that human metapneumovirus caused the ALRI 
symptoms in every instance. Thus, we estimated the ALRI 
burden that is causally attributable to human meta-
pneumo virus (ie, human metapneumovirus-attributable 
ALRI burden) by combining the human meta-
pneumovirus-associated ALRI burden estimates and the 
proportion of laboratory-confirmed human meta-
pneumovirus ALRI cases or deaths that are attributable to 
human metapneumovirus (the attrib utable fraction of 
human metapneumovirus in human metapneumovirus-
associated ALRI cases or deaths). We used a median value 
of 78% as the input for the attributable fraction of 
human meta pneumovirus-associated ALRI cases based 
on three multicountry studies.3–5 The attributable fraction 
of human meta pneumo virus-associated ALRI deaths was 
calculated using the attributable fraction of human meta-
pneumovirus-associated ALRI cases and the ratio between 
hCFRs of human metapneumovirus-positive ALRIs and 
human metapneumovirus-negative ALRIs. We assumed 
that hCFR of human metapneumovirus-negative ALRIs 
was equal to the hCFR of human metapneumovirus-
positive ALRIs that were not deemed attributable to 
human metapneumovirus (appendix p 17).
We did sensitivity analyses for human 
metapneumovirus-associated ALRI morbidity and in-
hospital deaths (appendix pp 9–13), and estimated burden 
by country development status, according to UNICEF 
definitions and World Bank income levels (low-income 
and lower-middle-income, upper-middle-income, and 
high-income).30,31 Additionally, we estimated the range 
of human metapneumovirus-associated ALRI hospital 
admissions by combining the proportion of hospitalised 
ALRI cases positive for human metapneumovirus and 
the 2015–16 estimates of all-cause ALRI hospital 
admissions among children younger than 5 years.32,33 
We also estimated overall human metapneumovirus-
associated ALRI deaths for settings with high child 
mortality by applying the proportion of human 
Figure: Flow diagram for selection of studies on human metapneumovirus-associated ALRIs
ALRIs=acute lower respiratory infections.
5172 records identified through database search
1583 duplicates removed
2565 records excluded as not relevant to topic
40 unpublished studies from the collaboration 
network (mutually exclusive to the published 
studies)
1110 full-text articles excluded
590 no data for children aged 0–59 months
202 irrelevant to human metapneumovirus
204 no rate for full seasons or for complete 
calendar years
81 duplicate data
4 no denominator
5 reported modelled estimates
3 in people with high-risk conditions
10 abstracts only
1 unable to translate (Arabic)
3789 records screened
1224 full-text articles assessed for eligibility
114 articles included (119 studies)
200 records identified through other sources
Studies with incidence rates
11 human metapneumovirus- 
associated ALRI
4 human metapneumovirus- 
associated severe ALRI
Studies with hospital admission 
rates
39 human metapneumovirus-
       associated ALRI
14 human metapneumovirus- 
associated ALRI with 
hypoxaemia
115 studies with data on 
proportion of hospitalised 
ALRI cases positive for 
human metapneumovirus 
and in-hospital case-fatality 
ratios 
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metapneumovirus-positive deaths among all ALRI deaths 
to the number of ALRI deaths in children under 5 years 
for 2017.1 The proportion of human metapneumovirus-
positive deaths among all ALRI deaths was estimated 
using data from hospital-based studies included in the 
systematic review.
As a final sensitivity analysis, we estimated human 
metapneumovirus-attributable mortality for settings 
with high child mortality by applying the proportion of 
human metapneumovirus–attributable ALRI deaths to 
the number of ALRI deaths in children under 5 years 
from 2017.1 The proportion of human metapneumovirus-
attributable ALRI deaths was estimated using data 
for December, 2016, to October, 2019, obtained from 
Child Health and Mortality Prevention Surveillance 
(appendix p 18).34 Details of included studies are in 
the appendix (pp 34–53, 60–67). All analyses were 
done in R (version 3.5.2).35 This study was done in 
accordance with the Guidelines for Accurate and 
Transparent Health Estimates Reporting recommen-
dations (appendix p 59).36
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. XW and HN had full access to all the data in 
the study and HN had final responsibility for the decision 
to submit for publication.
Results
We identified 159 studies with data on human meta-
pneumovirus-associated ALRI com munity incidence, 
hospital admission rates, the proportion of human 
metapneumovirus-positive cases among hospitalised 
ALRI cases, and hCFRs (figure); 119 studies were published 
and 40 were unpublished studies from the Respiratory 
Virus Global Epidemiology Network. Of the 159 studies 
included, seven (4%) were from low-income countries, 
36 (23%) from lower-middle-income countries, 67 (42%) 
from upper-middle-income countries, and 49 (31%) from 
high-income countries. The characteristics of the included 
studies are summarised in the appendix (pp 6–7, 34–53).
11 studies reported the incidence of human 
metapneumovirus-associated ALRIs (ie, ALRI cases with 
laboratory confirmation of human metapneumovirus). 
Ten studies provided data for the 0–59-month age group 
after imputation, including six studies from settings 
with high child mortality; five studies were from lower-
middle-income countries, two studies from upper-
middle-income countries, and three studies from 
high-income countries (table 1). Four studies reported 
incidence before 2010. Between 1990 and 2015, the mean 
human metapneumovirus-associated ALRI incidence 
meta-estimate was 22·1 per 1000 children per year 
(95% CI 17·0–28·7) in children aged 0–59 months in 
settings with high child mortality, and 18·9 (11·2–31·9) 
in settings with low child mortality. The high incidence 
For more on Child Health and 
Mortality Prevention 
Surveillance see 
https://champshealth.org/
LMICs UMICs HICs Settings with low 
child mortality
Settings with high 
child mortality
0–5 months
Studies, n 5 1 0 0 6
Incidence (per 1000 children per year)* 30·2 (7·8–109·8) NA NA NA 35·4 (12·0–99·3)
Episodes (thousands) 1337 (359–4983) NA NA NA 1629 (570–4662)
6–11 months
Studies, n 5 1 0 0 6
Incidence (per 1000 children per year)* 30·7 (12·2–75·1) NA NA NA 32·8 (16·0–65·9)
Episodes (thousands) 1347 (546–3327) NA NA NA 1496 (740–3026)
12–59 months
Studies, n 4 1 0 0 5
Incidence (per 1000 children per year)* 23·1 (16·7–31·9) NA NA NA 21·0 (15·4–28·6)
Episodes (thousands) 7923 (5743–10 933) NA NA NA 7490 (5506–10 192)
0–59 months†
Studies, n‡ 5 (1) 2 (1) 3 (2) 4 (3) 6 (1)
Incidence (per 1000 children per year)* 21·3 (15·5–29·3) 16·5 (8·3–32·8) 22·6 (13·4–38·2) 18·9 (11·2–31·9) 22·1 (17·0–28·7)
Episodes (thousands) 9202 (6711–12 620) 3019 (1521–5996) 1436 (854–2415) 4347 (2588–7304)§ 9891 (7620–12 842)§
Data in parentheses are estimated uncertainty ranges. Data were imputed using a multiple imputation approach. Meta-analyses were only done when two or more studies 
were available. Settings in which the under-5 mortality rate was higher than the median under-5 mortality rate for 2018, were considered high child mortality settings, and 
settings in which the under-5 mortality rate was lower than the median under-5 mortality rate for 2018, were considered low child mortality settings. LMICs=lower-middle 
income countries. UMICs=upper middle-income countries. HICs=high-income countries. NA=not available. *Derived from meta-analysis. †Estimates were calculated by 
applying rates for children aged 0–59 months to the population estimates. ‡Data in parentheses are the number of imputed studies. §Global number of human 
metapneumovirus-associated acute lower respiratory infections cases in children aged 0–59 months was 14·2 million (uncertainty range 10·2 million to 20·1 million), which 
was calculated by adding estimates from the two child mortality setting groups.
Table 1: Estimates of the incidence (per 1000 children per year) and number of human metapneumovirus-associated acute lower respiratory infection 
cases in children younger than 5 years in the community in 2018, by age group, and by World Bank income level and level of child mortality by setting 
(low vs high)
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observed in settings with low child mortality was mainly 
driven by two Australian studies (done between 1996 and 
1999 and between 2010 and 2014).37,38 Using these meta-
estimates, we estimated that there were 14·2 million 
human metapneumovirus-associated ALRI cases 
(UR 10·2 million to 20·1 million) globally in children 
younger than 5 years.
We identified 39 studies reporting human meta-
pneumovirus-associated ALRI hospital admission rates, 
including 29 studies reporting data by three narrow age 
groups (0–5 months, 6–11 months, or 12–59 months; 
table 2). The hospital admission rate meta-estimate was 
more than four times higher in infants aged 0–5 months 
and 6–11 months (2·2–3·3 admissions per 1000 children 
per year) than children aged 12–59 months (0·3–0·6 
admissions per 1000 children per year) when stratified 
by World Bank income levels and child mortality settings. 
In the analysis stratified by child mortality settings, 
LMICs UMICs HICs Settings with 
low child 
mortality
Settings with 
high child 
mortality
Global 
estimates*
Human metapneumovirus-associated ALRIs
0–5 months
Studies, n 8 6 5 7 12 ··
Hospital admission rate (per 
1000 children per year)†
2·4 (1·6–3·5) 3·3 (1·6–7·1) 3·3 (2·2–5·1) 2·7 (1·8–4) 3·0 (1·9–4·9) ··
Hospital admissions (thousands) 106 (72–157) 61 (29–128) 21 (14–32) 62 (42–93) 138 (86–221) 200 (128–314)
6–11 months
Studies, n 7 5 4 5 11 ··
Hospital admission rate (per 
1000 children per year)†
2·7 (1·7–4·3) 2·5 (1–5·9) 2·8 (2·2–3·5) 2·2 (1·5–3·4) 2·7 (1·7–4·4) ··
Hospital admissions (thousands) 119 (75–188) 46 (19–111) 18 (14–22) 51 (34–76) 123 (77–198) 174 (110–274)
12–59 months
Studies, n 9 8 5 7 15 ··
Hospital admission rate (per 
1000 children per year)†
0·6 (0·3–1) 0·4 (0·2–0·8) 0·3 (0·2–0·7) 0·3 (0·2–0·5) 0·6 (0·4–0·8) ··
Hospital admissions (thousands) 206 (113–375) 59 (29–117) 15 (8–28) 55 (35–87) 214 (152–302) 269 (187–389)
0–59 months‡
Hospital admissions (thousands) 431 (260–720) 165 (77–356) 54 (36–83) 168 (110–255) 475 (315–721) 643 (425–977)
Human metapneumovirus-associated ALRIs with hypoxaemia
0–5 months
Studies, n 6 3 1 2 8 ··
Hospital admission rate (per 
1000 children per year)†
0·3 (0–2·1) 1·3 (0·3–5·4) NA 0·6 (0·2–1·5) 0·7 (0·2–2·5) ··
Hospital admissions (thousands) 13 (1–268) 24 (6–101) NA 14 (5–38) 32 (9–113) 46 (14–151)
6–11 months
Studies, n 6 3 1 2 8 ··
Hospital admission rate (per 
1000 children per year)†
0·4 (0·1–2) 0·3 (0·1–1·2) NA 0·3 (0·1–1·7) 0·5 (0·2–1·7) ··
Hospital admissions (thousands) 18 (4–78) 6 (2–19) NA 7 (2–28) 23 (8–66) 30 (10–94)
12–59 months
Studies, n 6 4 1 3 8 ··
Hospital admission rate (per 
1000 children per year)†
0·1 (0–0·2) 0·1 (0–0·7) NA 0 (0–0·1) 0·1 (0–0·3) ··
Hospital admissions (thousands) 34 (5–215) 15 (1–171) NA 1 (0–4) 36 (5–273) 37 (5–277)
0–59 months‡
Hospital admissions (thousands) 65 (10–560) 44 (9–291) NA 22 (7–70) 91 (22–452) 112 (29–522)
Data in parentheses are estimated uncertainty ranges. Meta-analyses were only done when at least two studies were available. Settings in which the under-5 mortality rate 
was higher than the median under-5 mortality rate for 2018, were considered high child mortality settings, and settings in which the under-5 mortality rate was lower than 
the median under-5 mortality rate for 2018, were considered low child mortality settings. ALRI=acute lower respiratory tract infection. LMICs=lower-middle-income 
countries. UMICs=upper-middle-income countries. HICs=high-income countries. NA=not available. *Global estimates by age strata are the sum of estimates by child 
mortality settings; global estimates for 0–59 months are the sum of estimates by age groups and child mortality settings. †Derived from the meta-analysis. ‡Estimates are 
the sum of estimates for all three age groups (0–5 months, 6–11 months, and 12–59 months).
Table 2: Hospital admission rates (per 1000 children per year) and hospital admissions of human metapneumovirus-associated ALRI in children younger 
than 5 years in 2018, by age group and by World Bank income levels and level of child mortality by setting (low vs high)
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we estimated that there were 643 000 human meta-
pneumovirus-associated ALRI hospital admissions (UR 
425 000–977 000) globally in children younger than 5 years 
in 2018, of which 374 000 (58%) occurred in infants.
14 studies included hospital admission rates for human 
metapneumovirus-associated ALRIs with hypoxaemia by 
three age groups, including five studies from settings 
with low child mortality (table 2). In the analysis stratified 
by child mortality settings, we estimated that, globally, 
112 000 (UR 29 000–522 000) hospital admissions were 
for human metapneumovirus-associated ALRIs with 
hypoxaemia in children aged 0–59 months in 2018, 
accounting for 17% (ie, 112 000 of 643 000 cases) of the 
human metapneumovirus-associated ALRI hospital 
admissions.
73 studies reported hCFRs for human meta-
pneumovirus-associated ALRI in children younger than 
5 years, including 28 studies with data stratified by three 
narrow age bands (table 3). hCFRs were highest in 
infants aged 0–5 months from settings with high child 
mortality (3·3%, 95% CI 1·7–6·1) and from lower-
middle-income countries (4·5%, 2·3–8·6). hCFRs were 
lower in children from high-income countries who were 
aged 6–11 months (0·6%, 0·1–3·9) and 12–59 months 
(0·5%, 0–7·0) than infants aged 0–5 months from high 
child mortality settings and from lower-middle-income 
countries, with the estimates in older children having 
notably wide confidence intervals. On the basis of these 
meta-estimates, we estimated that there were 7700 human 
metapneumovirus-associated ALRI in-hospital deaths 
(UR 2600–48 800) in children younger than 5 years in 
2018, of which 5500 (71%) occurred in infants. About 
64% of these deaths were in young infants aged 
0–5 months (4900 deaths of 7700 total in-hospital 
deaths), and 88% (6800 deaths of 7700 total in-hospital 
deaths) occurred in countries with high child mortality.
Across 28 countries or regions with low child mortality, 
22–94% of children with pneumonia received care from a 
health provider (appendix p 16). About 71% of the data 
were for the period 2010–14. On the basis of these data, we 
estimated the median inflation factor was 1∙3 across 
regions or countries, and thus that there were about 
1100 human metapneumovirus-associated ALRI deaths 
(UR 100–28 800; after rounding in-hospital deaths), in 
hospitals and in the community, among children younger 
than 5 years in settings with low child mortality in 2018. 
Of the eight sites with data on pneumonia mortality in 
high child mortality settings, five sites were in rural areas, 
and six sites were in African countries. Six studies reported 
data between 2010 and 2016, and the remaining two 
studies reported data from 2008 onwards. The inflation 
factor ranged from 1∙5 to 3∙5 across the eight sites, 
with a median value of 2∙2 (IQR 1·7–2·7). Thus, we esti-
mated that there were 14 900 human metapneumovirus-
associated ALRI deaths (UR 5600–59 700; after rounding 
in-hospital deaths), in hospitals and in the community, in 
settings with high child mortality. We therefore estimate 
that there were 16 100 human metapneumovirus-
associated ALRI deaths (5700–88 000; ie, ALRI deaths in 
children with laboratory-confirmed human metapneumo-
virus) among children globally in 2018.
By applying the attributable fraction of human meta-
pneumovirus to the estimated human metapneumovirus-
associated burden, we estimated that 11·1 million ALRI 
LMICs UMICs HICs Settings with low 
child mortality
Settings with high 
child mortality
Global estimates*
Studies, n 15 6 7 7 21 ··
0–5 months
hCFR, %† 4·5% (2·3–8·6) 1·7% (0·6–5·1) 0·4% (0–8·6) 0·4% (0–8·6) 3·3% (1·7–6·1) ··
Deaths, n 4300 (2000–9200) 1000 (300–3700) 100 (0–3400) 200 (0–9900) 4600 (2100–9900) 4900 (2100–19 300)
6–11 months
hCFR, %† 0·7% (0–9) NA 0·6% (0·1–3·9) 0·6% (0·1–3·9) 0·2% (0–7·6) ··
Deaths, n 900 (0–37 800) NA‡ 100 (0–700) 300 (0–1900) 200 (0–9400) 600 (100–11 300)
12–59 months
hCFR, %† 0·9% (0·3–2·8) 1·1% (0·1–9·1) 0·5% (0–7·0) 0·5% (0–7) 0·9% (0·2–3·6) ··
Deaths, n 1800 (500–6500) 600 (100–6600) 100 (0–2800) 300 (0–10 100) 1900 (400–8300) 2200 (400–18 300)
0–59 months§
Deaths, n 7200 (2600–52 300) 1700 (300–10 300) 300 (0–6900) 800 (100–22 200) 6800 (2500–27 100) 7700 (2600–48 800)
Data in parentheses are estimated uncertainty ranges. Settings in which the under-5 mortality rate was higher than the median under-5 mortality rate for 2018, were 
considered high child mortality settings, and settings in which the under-5 mortality rate was lower than the median under-5 mortality rate for 2018, were considered low 
child mortality settings. hCFR=in-hospital case-fatality ratio. ALRI=acute lower respiratory tract infection. LMICs=lower-middle-income countries. UMICs=upper middle-
income countries. HICs=high-income countries. NA=not available. *Global estimates by age strata are the sum of estimates by child mortality settings; global estimates for 
children aged 0–59 months are the sum of estimates by age and child mortality settings. †Estimates derived from the meta–analysis. ‡No human metapneumovirus-
associated ALRI deaths were reported in any of the studies from upper middle-income countries; thus hCFR for the strata was not estimated. §Estimates for the 0–59 month 
age group are the sum of estimates for the three age groups (0–5 months, 6–11 months, and 12–59 months).
Table 3: hCFR meta-estimates of human metapneumovirus-associated ALRI and in-hospital deaths in children younger than 5 years in 2018, by age 
group and by World Bank income levels and level of child mortality by setting (low vs high)
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cases (UR 8·0 million to 15·7 million) and 502 000 ALRI 
hospital admissions (UR 332 000–762 000) could be 
attributed to human metapneumovirus in children under 
5 years (table 4). We estimated that the ratio of in-hospital 
case fatalities of human metapneumovirus-attributable 
ALRIs to human metapneumovirus-associated cases was 
0·9 (appendix p 18), and the attributable fraction for 
human metapneumovirus-associated ALRI deaths was 
70% (appendix pp 17–18), indicating that 11 300 ALRI 
deaths (UR 4000–61 600) globally could be attributed to 
human metapneumovirus in 2018, including 10 400 deaths 
(3900–41 800) in settings with high child mortality (table 4).
We did several sensitivity analyses to estimate 
hospital admissions, in-hospital deaths, and overall human 
metapneumovirus-associated ALRI deaths, and of human 
metapneumovirus-attributable ALRI deaths (by country 
development strata and World Bank income level) using 
different approaches (appendix pp 8–13,16,19). For global 
human meta pneumovirus-associated ALRI hospital 
admis sions, the estimates in children younger than 5 years 
ranged from 626 000 to 650 000 in analyses by different 
stratification groups (appendix p 9); the proportion-based 
approach yielded a broader range (282 000–902 000; 
appendix p 10). The point estimate of global in-hospital 
deaths ranged from 7200 to 9100 in children younger than 
5 years, and an estimated 79% of the global in-hospital 
deaths occurred in low-income and lower-middle-income 
countries (7200 of 9100 deaths) when stratified by World 
Bank income level (appendix p 11). We estimated 
19 900 human metapneumovirus-associated ALRI deaths 
(UR 12 100–33 200) and 9900 human metapneumovirus-
attributable ALRI deaths (UR 2600–39 300) in children 
aged 1–59 months in settings with high child mortality 
using a different approach (appendix pp 16, 19).
Discussion
To our knowledge, this is the first study to report global 
human metapneumovirus-associated ALRI burden 
estimates both among children younger than 5 years 
overall and stratified by narrow age groups (0–5 months, 
6–11 months, and 12–59 months). When compared with 
our previously published all-cause ALRI burden 
estimates, human metapneumovirus is identified in 
11% of ALRI cases, 4–13% of ALRI hospital admissions, 
and 2% of ALRI deaths among children under 5 years 
globally.1,32,33 About 8% of ALRI cases, 3–10% of ALRI 
hospital admissions, and 1% of ALRI mortality can be 
attributed to human metapneumovirus. The wide URs 
of these burden estimates reflect differences across 
studies, arising from variation in human metapneumo-
virus epidemiology between populations and methodo-
logical differences, and from paucity of data, especially 
mortality data.
Similar to respiratory syncytial virus and influenza, we 
found that the human metapneumovirus-associated 
ALRI hospital admission rate was much higher in 
infants than older children, with about 58% of hospital 
admissions and 71% of in-hospital deaths due to human 
metapneumovirus-associated ALRIs in children under 
5 years occurring in the first year of life.18,19 The high 
burden in infants could be due to the immaturity 
of infants’ immune systems and decaying maternal 
antibodies during the first several months of life.39,40 The 
consistently high human metapneumovirus-associated 
ALRI hospital admission rate among infants across 
different settings highlights the importance of developing 
safe and effective maternal human metapneumovirus 
vaccines, particularly for infants.
Our hCFR estimates show that young infants aged 
0–5 months are at an increased risk of human 
metapneumovirus–associated ALRI mortality compared 
with infants older than 5 months. hCFR estimates for 
infants aged 0–5 months varied sub stantially across 
settings, possibly reflecting the differences in disease 
severity at admission and in the quality of hospital care. 
Increased disease severity at presentation could be 
associated with the high prevalence of certain underlying 
conditions and delays in care-seeking.3,33 The case-fatality 
ratio (overall and in-hospital) and overall mortality due to 
ALRI among children under 5 years has substantially 
reduced in the past 15 years due to socioeconomic 
development, reduced prevalence of pneumonia risk 
Attributable 
fraction, %*
Global human 
metapneumovirus-
associated burden 
estimates
Global human 
metapneumovirus-
attributable burden 
estimates†
Human metapneumovirus-attributable ALRI cases (millions) 78%‡ 14·2 (10·2–20·1) 11·1 (8·0–15·7)
Human metapneumovirus-attributable ALRI hospital admissions (thousands) 78% 643 (425–977) 502 (332–762)
Human metapneumovirus-attributable ALRI deaths 70%§ 16 100 (5700–88 000) 11 300 (UR 4000–61 600)
Data in parentheses are uncertainty ranges. ALRI=acute lower respiratory tract infection. *The proportion of human metapneumovirus-positive cases and deaths attributable 
to human metapneumovirus. †Applying the corresponding attributable fraction to the estimates of human metapneumovirus-associated burden. ‡The attributable fraction 
for human metapneumovirus-associated ALRI cases was calculated using odds ratios from a systematic review and two multi-country studies; the median odds ratio from 
the three studies was input to yield the attributable fraction for human metapneumovirus-ALRI cases (78%); all references are in the appendix (p 18). §The attributable 
fraction for human metapneumovirus-associated ALRI deaths was modelled using the attributable fraction for human metapneumovirus cases and the ratio of case-fatality 
between human metapneumovirus-attributable cases and human metapneumovirus-associated cases (appendix pp 17–18).
Table 4: Estimates of global human metapneumovirus-attributable ALRI cases, hospital admissions, and mortality, projected using attributable fractions 
that were calculated by use of inflation factors
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factors, and increased use of interventions.33,41 However, 
most studies spanning several years reported one to three 
deaths from human metapneumovirus-associated ALRIs, 
and we were unable to identify any changes in the hCFR of 
human metapneumovirus-associated ALRI over time. 
When stratifying the data using 2010 as a cutoff and using 
available age-stratified data from studies done before 2010 
(eligible if part of a study was done before 2010 and data 
could not be stratified by year), we estimated that there 
were 9600 human metapneumovirus-associated ALRI in-
hospital deaths (UR 2300–51 200) among children under 
5 years in 2010 (appendix p 12).
For settings with high child mortality, the inflation 
factor was based on scarce data.19 The estimates could be 
biased due to limited generalisability and location-specific 
characteristics (ie, prevalence of human metapneumovirus 
in childhood ALRI deaths). However, our reported esti-
mates of overall human metapneumovirus-associated 
ALRI deaths for settings with high child mortality are 
conservative and could increase by approximately 30% 
(19 900 deaths) using an alternative estimation approach 
(appendix p 16). For settings with low child mortality, the 
inflation factor and overall mortality estimate are likely to 
be underestimated because the definition of care-seeking 
is broader than the definition of in-hospital care: contact 
with primary care is included as care-seeking in surveys, 
but not included in the in-hospital mortality estimates in 
the present analysis. The US vital statistics data showed 
that about 40% of under-5 ALRI deaths (International 
Classification of Diseases, 10th revision diagnostic codes 
J09–22; U04) occurred in outpatient or emergency 
departments between 2010 and 2017.42 Additionally, this 
analysis was based on one further assumption that no 
differences exist between the case-fatality ratio for 
hospitalised and non-hospitalised pneumonia cases. The 
direction of bias associated with this assumption could be 
complicated by the two-way association between disease 
severity and care-seeking: children with more severe 
symptoms are more likely to receive hospital care; whereas, 
supportive care in hospitals can reduce the risk of death, 
and lack of appropriate care or delays in care can lead to 
rapid deterioration.43–45 Moreover, data on pneumonia care-
seeking in high-income countries were not available in 
published reports; extrapolation from other countries with 
low child mortality to high-income countries might result 
in bias. The estimates of inflation factor could also be 
affected by accuracy of assessment and completeness of 
documentation for ALRI or pneumonia. For example, the 
diagnosis of (presumptive) pneumonia in the UNICEF 
dataset is based on caregivers’ report, thus might be 
inaccurate and affect the estimates of inflation factor.
Our study had several other limitations. Little data were 
available for Europe and Latin America, which could have 
affected the generalisation of the estimates. Moreover, 
heterogeneity in the methodology (ie, variations in precise 
case definitions, proportion of eligible ALRI cases tested 
for human metapneumovirus) existed across studies for 
each outcome and is likely to have biased our estimates 
(appendix p 7). We adjusted for levels of testing when 
estimating hospital admission rates by assuming that the 
proportion of tested patients with ALRIs who were positive 
for human metapneumovirus was the same as the 
proportion in untested patients with ALRIs. However, 
we did not adjust for the underdetection of human 
metapneumovirus when estimating hCFRs. The hCFR 
of human metapneumovirus-associated ALRIs and in-
hospital mortality might be underestimated, as suggested 
by the higher hCFR in patients tested than untested 
patients (appendix p 24). The incidence and hospital 
admission rates of human metapneumovirus-associated 
ALRI are unlikely to be affected by the accuracy of test 
methods since 92% of the studies used PCR to detect 
human metapneumovirus. In addition to potential biases, 
we summed yearly data to ensure precision in the age-
stratified analysis; however, we did not account for 
variation across years (appendix p 20).
Our results show that infants younger than 1 year 
have disproportionately high risks of severe human 
metapneumovirus infections across settings. Infants 
aged 0–5 months in low-income and lower-middle-
income countries have an increased risk of mortality 
from human metapneumovirus-associated ALRIs com-
pared with those in upper-middle-income countries and 
high-income countries, accounting for nearly eight of 
every ten global deaths occurring in this age group. 
These estimates highlight the importance of inter-
ventions for infants. In low-income and lower-middle-
income countries, continued efforts are needed to reduce 
human metapneumovirus-associated ALRI mortality 
among young children, especially infants, in hospitals 
and communities through improving access to care and 
case management in hospitals. Considering the paucity 
of data at the regional level, these estimates should be 
viewed as preliminary estimates. In the future, additional 
high quality data on childhood human metapneumovirus-
associated ALRI cases, hosp ital admissions, and mortality, 
especially age-stratified data, would help refine the 
estimates and track changes in human metapneumovirus-
associated ALRI morbidity and mortality over time.
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